Yip, Terry Cheuk-Fung Lai, Jimmy Che-To Wong, Grace Lai-Hung
Published in
Journal of Gastroenterology
Reducing the incidence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB) is the key ultimate goal set in essentially all treatment guidelines. There has been solid evidence supporting the relationship between serum hepatitis B virus (HBV) DNA level and risk of HCC. Antiviral treatment with oral nucleos(t)ide analogues (NA...
Seo, Jun Won Kim, Kichun Jun, Kang Il Kang, Chang Kyung Moon, Song Mi Song, Kyoung Ho Bang, Ji Hwan Kim, Eu Suk Kim, Hong Bin Park, Sang Won
...
Published in
Infection & chemotherapy
Tenofovir disoproxil fumarate (TDF)-induced nephrotoxicity is related to high plasma tenofovir concentrations. Tenofovir alafenamide (TAF) is a tenofovir prodrug with 90% lower plasma tenofovir concentrations. The aim of this study was to evaluate changes in tenofovir-induced nephrotoxicity in Human Immunodeficiency Virus (HIV)-positive patients wh...
Heron, Jack E. Bloch, Mark Vanguru, Vinay Saunders, John Gracey, David M.
Published in
BMC Nephrology
BackgroundThe nucleotide reverse transcriptase inhibitor Tenofovir Alafenamide (TAF) is a novel pro-drug of tenofovir (TFV) and possesses a superior renal safety profile compared with tenofovir disoproxil fumerate (TDF). Due to unique pharmacokinetic characteristics, treatment with TAF is not associated with significant renal proximal tubular accum...
Charlton, Michael R. Alam, Altaf Shukla, Akash Dashtseren, Bekhbold Lesmana, Cosmas Rinaldi Adithya Duger, Davadoorj Payawal, Diana Alcantara Duy Cuong, Do Jargalsaikhan, Ganbolor Cua, Ian Homer Yee
...
Published in
Journal of Gastroenterology
Asia has intermediate-to-high prevalence and high morbidity of hepatitis B virus (HBV) infection. The use of guideline-recommended nucleos(t)ide analogs with high barrier to resistance, such as entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF), is one of the key interventions for curbing HBV infection and associa...
Mayer, Kenneth H. Agwu, Allison Malebranche, David
Published in
Advances in Therapy
Pre-exposure prophylaxis (PrEP) is a way of preventing HIV. By taking a daily pill, which contains two medicines, HIV can be stopped before it causes an infection. PrEP is prescribed for people at risk of HIV infection. However, many people who are at risk do not use PrEP. We explored the reasons for this. We found that many individuals at risk had...
Xiao, Deqing Ling, Kah Hiing John Tarnowski, Thomas Majeed, Sophia R German, Polina Kearney, Brian P Zhao, Yuwen Chen, Yuan-Shek Ma, Lili Zhang, Tianyi
...
Published in
Analytical biochemistry
Tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are both tenofovir (TFV) prodrugs, with the same active intracellular metabolite, TFV-diphosphate (TFV-DP). TAF delivers TFV-DP to target cells more efficiently and at lower doses than TDF, thereby substantially reducing systemic exposure to TFV, which results in improved bone and ...
Turner, Dane Drak, Douglas O’Connor, Catherine C. Templeton, David J. Gracey, David M.
Published in
AIDS Research and Therapy
BackgroundTenofovir disoproxil fumarate (TDF) is widely used in the management of HIV-infection, but has been associated with renal impairment in a small proportion of patients. Tenofovir alafenamide (TAF), a novel prodrug of tenofovir, causes less renal impairment and can improve renal function in patients switched from TDF. The factors which pred...
Surial, Bernard Cavassini, Matthias Calmy, Alexandra Fehr, Jan Stöckle, Marcel Bernasconi, Enos Roth, Bianca Fux, Christoph A. Kovari, Helen Furrer, Hansjakob
...
Published in
BMC Infectious Diseases
BackgroundTenofovir alafenamide (TAF)-containing combinations were introduced in Switzerland after October 2016 and are recommended over tenofovir disoproxil fumarate (TDF) in patients with osteoporosis or impaired renal function.MethodsWe included all participants of the Swiss HIV Cohort Study on TDF-containing antiretroviral therapy with follow-u...
Liang, Lilian Yan Wong, Grace Lai-Hung
Published in
Clinical and Molecular Hepatology
Despite all these exciting developments, there remain some unmet needs in the management for patients with chronic hepatitis B (CHB). As majority of CHB patients are going to use oral nucleos(t)ide analogues (NAs) for decades, Safety profile of NAs is of no doubt an important issue. The newest nucleotide analogue tenofovir alafenamide is potent in ...
Mandal, Subhra Kang, Guobin Prathipati, Pavan Kumar Zhou, You Fan, Wenjin Li, Qingsheng Destache, Christopher J
Published in
Journal of controlled release : official journal of the Controlled Release Society
Daily oral antiretroviral (ARV) drugs for pre-exposure prophylaxis (PrEP) has proven efficacy for diverse groups of high-risk individuals. However, daily dosing regimen has augmented non-adherence. These experiments comparatively investigated the long-acting (LA) PrEP potency of subcutaneous (SubQ) administrated tenofovir alafenamide (TAF) and emtr...
